Globus Medical (GMED)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$78.29+0.22%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GMED
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $78 GMED trades at 16× p/e, below its 28× p/e peer median. Our $111 fair value sits well above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $80–$117. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $100.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $214.36 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $218.06 | — | — | Hist. CAGR | high |
| graham number | 12M | $61.99 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$80.00 – $117.00 (median $100.00) · 8 analysts · as of 2026-07-28
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 51% over what the business is worth with no growth; closing that gap needs roughly 21.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $3.26/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $25.48 |
| 6.2 |
| 3.53 |
| TTM |
| high |
| Peer P/FCF | 12M | $134.65 | 24.6 | 5.46 | TTM | high |
| Peer P/E | 12M | $98.44 | 18.7 | 5.26 | ntm analyst | high |
| Peer P/S | 12M | $67.38 | 2.9 | 22.89 | TTM | high |
| PEG | 12M | $162.37 | 33.0 | 4.92 | TTM | high |
| residual income | 12M | $41.64 | — | — | TTM | high |
| Own P/E history | 12M | $89.24 | 18.1 | 4.92 | TTM | high |
| triangulated | 12M | $148.13 | 28.3 | 5.24 | Triangulated | high |
| Peer P/FCF | 3Y | $204.78 | 24.6 | 8.31 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $103.88 | 18.7 | 5.55 | Analyst | medium |
| Peer P/S | 3Y | $74.93 | 2.9 | 25.46 | guidance | medium |
| PEG | 3Y | $183.20 | 33.0 | 5.55 | Analyst | medium |
| Own P/E history | 3Y | $100.69 | 18.1 | 5.55 | Analyst | medium |
| Peer P/FCF | 5Y | $270.82 | 24.6 | 10.99 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $107.55 | 18.7 | 5.75 | Analyst | high |
| Peer P/S | 5Y | $77.58 | 2.9 | 26.36 | guidance | high |
| PEG | 5Y | $189.67 | 33.0 | 5.75 | Analyst | high |
| Own P/E history | 5Y | $104.25 | 18.1 | 5.75 | Analyst | high |